Respiratory Syncytial Virus InfectionsPhase 2NCT04785612
Study of RSVpreF Vaccination and RSV Challenge in Healthy Adults
A Phase 2 study testing RSVPreF in people with Respiratory Syncytial Virus Infections, run by Hvivo at 1 site in United Kingdom.
Trial summary
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later. Read more about this study
- Who is it for?
- Ages 18 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Respiratory Syncytial Virus Infections
- What is being tested?
- RSVPreF
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 70 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 10 Nov 2020to 16 Aug 2021
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- An informed consent document signed and dated by the participant and the Investigator.
- Aged between 18 and 50 years.
- In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety.
- A documented medical history prior to enrolment.
- The following criteria are applicable to female participants participating in the study.
- Females of childbearing potential must have a negative pregnancy test prior to enrolment.
Show all 16Show fewer
- Females of non-childbearing potential:
- <!-- -->
- Post-menopausal females; defined as having a history of amenorrhea for >12 months with no alternative medical cause, and /or by FSH level >40mIU/mL, confirmed by laboratory.
- Documented status as being surgically sterile (e.g. tubal ligation, hysterectomy, bilateral salpingectomy and bilateral oophorectomy).
- The following criteria apply to female and male participants:
- Female participants of childbearing potential must use one form of highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 28 days after the date of viral challenge/last dosing with IMP (whichever occurs last).
- Male participants must agree to the contraceptive requirements below at entry to quarantine and continuing until 28 days after the date of Viral challenge / last dosing with IMP (whichever occurs last): a. Use a condom with a spermicide to prevent pregnancy in a female partner or to prevent exposure of any partner (male and female) to the IMP. b. Male sterilisation with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate (please note that the use of condom with spermicide will still be required to prevent partner exposure). This applies only to males participating in the study. c. In addition, for female partners of child bearing potential, that partner must use another form of contraception such as one of the highly effective methods mentioned above for female participants.
- In addition to the contraceptive requirements above, male participants must agree not to donate sperm following discharge from quarantine until 28 days after the date of Viral Challenge/last dosing with IMP (whichever occurs last).
- True abstinence - sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
- Sero-suitable to the challenge virus.
Who cannot join
- History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit.
- a) Any history or evidence of any other clinically significant or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety).
- And/or other major disease that, in the opinion of the Investigator, may put the participant at undue risk, or interfere with a participant completing the study and necessary investigations (e.g autoimmune disease or immunodeficiency).
- Participants who have smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years].
- A total body weight ≤ 50 kg and Body Mass Index (BMI) ≤18 kg/m2 and ≥30kg/m2.
- Females who:
Show all 25Show fewer
- Are breastfeeding, or
- Have been pregnant within 6 months prior to the study.
- History of anaphylaxis-and/or a history of severe allergic reaction or significant intolerance to any food or drug or vaccine, including hypersensitivity to any of the constituents of the study vaccine, as assessed by the PI.
- Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
- a) Any significant abnormality altering the anatomy of the nose in a substantial way b) Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months c) Any nasal or sinus surgery within 3 months
- a) Evidence of vaccinations with licensed live attenuated vaccines within the 4 weeks prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first). Evidence of vaccinations with licensed vaccines which are not live attenuated within the 2 weeks prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
- Intention to receive any vaccination(s) before at least 28 days after the viral challenge (NB. No travel restrictions will apply after the Day 28 Follow-up visit).
- Receipt of blood or blood products, or loss (including blood donations) of 550 mL or more of blood during the 2 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first) or planned during the 2 months after the viral challenge.
- a) Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
- Previous vaccination with any licensed or investigational RSV vaccine before enrolment into the study. c) Receipt of three or more investigational drugs within the previous 12 months prior to the planned date of viral challenge/first dosing with IMP (whichever occurs first).
- Prior inoculation with a virus from the same virus-family as the challenge virus.
- Prior participation in another human viral challenge study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study.
- Receipt of treatment with immunosuppressive therapy.
- a) Confirmed positive test for drugs of abuse and cotinine on first study visit. One repeat test allowed at PI discretion.
- History or presence of alcohol addiction, or excessive use of alcohol
- A forced expiratory volume in 1 second (FEV1) < 80%.
- Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test.
- Those employed or immediate relatives of those employed at hVIVO, Pfizer or any vendor.
- Any other finding that, in the opinion of the Investigator, deems the Participant unsuitable for the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later. The purpose of this research study is to assess the safety, immunogenicity and efficacy of RSVpreF using a human viral challenge model.
Read the detailed description
Respiratory Syncytial Virus (RSV) is a common virus that affects all human age groups and can cause a range of respiratory disease such as bronchitis and lower respiratory infections. These serious illnesses affect infants and adults who are older especially if they are over 65, have chronic heart or lung disease or have a weakened immune system. Vaccination against RSV has the potential to be a highly beneficial and effective approach to reduce RSV disease in older adults and pediatric populations, however there is no current vaccine approved for the prevention of RSV infections.
RSVpreF is being developed to prevent RSV-associated moderate to severe lower respiratory tract disease in adults 60 years of age and in infants by active immunization of pregnant women.
This study is an exploratory proof-of-concept to assess the safety, immunogenicity and efficacy of RSVpreF using a human challenge model. The RSV challenge model is developed to help understanding the RSV disease and assess new vaccines by testing them in participants deliberately infected with the virus.
In this study, approximately 62 (up to 72) participants will be vaccinated with the investigational RSVpreF to account for withdrawals between vaccination and challenge. Participants will be randomised 1:1 to receive RSVpreF or placebo.
The study will consist of a vaccination phase, quarantine phase and a follow-up phase.
- Conditions
- Respiratory Syncytial Virus Infections
- Being tested
- RSVPreF, Placebo
- Medical subject headings
- Respiratory Syncytial Virus Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RSVPreFBiological
A single dose of 120 mcg RSVpreF for intramuscular injection
PlaceboOther
A single Placebo dose for intramuscular injection to match experimental vaccine
| Study group | Role | What they receive |
|---|---|---|
| RSVPreF | Experimental | A single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume Receives: Biological: RSVPreF |
| Placebo | Placebo comparator | A single intramuscular injection of Placebo to match active vaccine Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Viral Load-time Curve (VL-AUC) of RSV
The VL-AUC of RSV determined by qRT-PCR from nasal wash samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Measured: Day 2 to Day 12
Number of Participants With RT-PCR Confirmed (Detected) Incidence of Symptomatic Infection
RT-PCR-confirmed symptomatic RSV infection defined as:
- Two detectable qRT-PCR reported on 2 or more consecutive days (any two detectable (≥LLOD) qRT-PCR measurements reported over 4 consecutive scheduled timepoints). and
- Either one or more positive clinical symptoms from different categories in the symptom scoring system or one Grade 2 symptom from any category
Measured: Day 2 to Day 12
Sum Total Symptoms Diary Card Score (TSS)
The sum total symptoms score is the sum of all scores from the first assessment on Day 1 to the first assessment on Day 12 (34 assessments). Symptom scores were collected three times daily starting one day post-viral challenge (Day +1) up to discharge from quarantine using a participant self-reportable 13-symptoms card. Clinical symptoms include runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze. Participants scored symptoms from 0 (no symptoms) - 3 (severe). Shortness of breath and wheeze had an additional scoring option of grade 4. For each assessment, an individual total symptom score was derived as the total of the scores given to the 13 symptoms on that symptom score card. Individual total symptom scores ranged from 0 (if all symptoms graded 0) to 41 (if all symptoms graded 3 and shortness of breath and wheeze graded 4).
Measured: Day 1 to Day 12
Secondary outcomes (24)
Number of Participants With RT-PCR Confirmed (Quantifiable) Incidence of Symptomatic Infection
RT-PCR confirmed RSV infection defined as
- Two quantifiable PCR measures reported on 2 or more consecutive days (any two quantifiable (≥LLOQ) qRT-PCR measurements reported over 4 consecutive scheduled timepoints), and
- Either one or more positive clinical symptoms from different categories in the symptom scoring system or one Grade 2 symptom from any category
Measured: Day 2 to Day 12
Number of Participants With Culture Lab-confirmed Reduction of Symptomatic RSV Infection
Culture lab-confirmed symptomatic RSV infection defined as:
- One quantifiable viral culture and
- Either one or more positive clinical symptoms from different categories in the symptom scoring system or one Grade 2 symptom from any category
Measured: Day 2 to Day 12
Peak Viral Load of RSV by qRT-PCR
Reduction in Peak viral load of RSV determined by quantifiable qRT-PCR from nasal samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Measured: Day 2 to Day 12
Peak Viral Load of RSV by Viral Culture
Peak viral load of RSV determined by quantifiable viral culture from nasal samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Measured: Day 2 to Day 12
Duration of Quantifiable qRT-PCR Measurements
Duration (time in hours) of quantifiable qRT-PCR measurements from nasal samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Measured: Day 2 to Day 12
Duration of Quantitative Viral Culture Measurements
Duration (time in hours) of quantitative viral culture measurements from nasal samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Measured: Day 2 to Day 12
VL-AUC Determined by Quantitative Viral Culture
VL-AUC of RSV as determined by quantitative viral culture on nasal samples starting two days post-viral challenge (Day +2) up to discharge from quarantine
Measured: Day 2 to Day 12
Area Under the Curve Over Time of Total Clinical Symptoms (TSS-AUC)
Data presented is hours * score. TSS-AUC (trapezium rule) as measured by graded symptom scoring system collected 3 times daily starting Day +1 up to Day 12am using a participant self-reportable 13-symptoms card, the max number of diary cards included in the AUC calculation is 34, the maximum time period is 264hrs.
Clinical symptoms included runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze. Participants scored symptom from 0 (no symptoms) - 3(severe). Shortness of breath and wheeze had an additional scoring option of grade 4. Dairy card total symptom scores ranged from 0 (if all symptoms graded 0) to 41 (if all symptoms graded 3 and shortness of breath and wheeze graded 4).
The range of TSS AUC scores are between 0 and 10,824 hours*score (maximum of 264x41).
Measured: Day 1 to Day 12
Peak Symptoms Diary Card Score
Peak TSS for each participant is defined as the diary card total with the worst score (highest). The symptom scoring system was collected three times daily starting one day post-viral challenge (Day +1) up to discharge from quarantine using a participant self-reportable 13-symptoms card. Clinical symptoms include runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze. Participants scored symptoms from 0 (no symptoms) - 3 (severe). Shortness of breath and wheeze had an additional scoring option of grade 4. For each assessment, an individual total symptom score was derived as the total of the scores given to the 13 symptoms on that symptom score card. Individual total symptom scores ranged from 0 (if all symptoms graded 0) to 41 (if all symptoms graded 3 and shortness of breath and wheeze graded 4).
Measured: Day 1 to Day 12
Peak Daily Symptom Score
Peak daily symptom score was derived, for each day from Day 1 to Day 12, as the maximum of the 3 total symptoms scores on that day, providing 11 scores each. The symptoms were collected three times daily starting one day post-viral challenge (Day +1) up to discharge from quarantine using a participant self-reportable 13-symptoms card. Clinical symptoms include runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze. Participants scored symptoms from 0 (no symptoms) - 3 (severe). Shortness of breath and wheeze had an additional scoring option of grade 4. For each assessment, an individual total symptom score was derived as the total of the scores given to the 13 symptoms on that symptom score card. Individual total symptom scores ranged from 0 (if all symptoms graded 0) to 41 (if all symptoms graded 3 and shortness of breath and wheeze graded 4).
Measured: Day 1 to Day 12
Percentage Number of Participants With Grade 2 or Higher Symptoms
Number (%) of participants with Grade 2 or higher symptoms (on any occasion from Day 1 to Day 12)
Measured: Day 1 to Day 12
Number of Participants With an Occurrence of at Least Two Positive Quantifiable qRT-PCR Measurements on 2 or More Consecutive Days
The number of participants with at least two quantifiable positive (≥LLOQ) qRT-PCR nasal sample measurements across 4 consecutive visits
Measured: Day 2 to Day 12
Number of Participants With an Occurrence of at Least Two Positive Detectable qRT-PCR Measurements on 2 or More Consecutive Days
The proportion of participants with at least two positive detectable qRT-PCR nasal sample measurements across 4 consecutive visits
Measured: Day 2 to Day 12
Number of Participants With an Occurrence of at Least One Positive Quantitative Cell Culture Measurements
The proportion of participants with at least one quantifiable positive (≥LLOQ) nasal sample viral culture starting two days post-viral challenge (Day+2) up to discharge from quarantine. Viral culture is only done for samples where qRT-PCR is positive (detectable), when the qRT-PCR is negative the viral culture is assumed to be 0 for any endpoint derivations.
Measured: Day 2 to Day 12
Total Mucus Weight
Total weight of mucus produced starting one day post-viral challenge (Day +1) up to discharge from quarantine.
The mean sum of all mucus produced from Day 1 to Day 12 is reported in data table.
Measured: Day 1 to Day 12
Total Tissue Number
Total number of tissues used by participants starting one day post-viral challenge (Day +1) up to discharge from quarantine.
Measured: Day 1 to Day 12
Number of Solicited Local Reactions Within 7 Days After Vaccination
Local reactions include pain at injection site, redness and swelling
Measured: 7 days post vaccination
Number of Systemic Events Within 7 Days After Vaccination
Systemic reactions included fever, fatigue, headache, vomiting, nausea, diarrhea, muscle pain, and joint pain. Each of these items was collected on a four-point scale including, none, mild, moderate, and severe.
Measured: 7 days post vaccination
Number of Participants With an Occurrence of Unsolicited Adverse Events (AEs) Post Vaccination
Number of participants with at least one unsolicited adverse events (AEs) within 30 days after vaccination. Unsolicited AEs were all AEs for which participants were not specifically questioned in the participant diary.
Measured: 30 days
Occurrence of Medically Attended AEs
Number of medically attended AEs from vaccination to study end
Measured: Through study completion, an average of 6 months
Occurrence of SAEs
Number of SAEs from vaccination to study end
Measured: Through study completion, an average of 6 months
Number of Participants With an Occurrence of Unsolicited AEs Related to Viral Challenge
Number of participants with at least one unsolicited AE within 30 days post-viral challenge (Day 0) up to Day +28 follow up. Unsolicited AEs were all AEs for which participants were not specifically questioned in the participant diary.
Measured: Day 0 to Day 28
Occurrence of Haematological and Biochemical Laboratory Abnormalities During the Quarantine Period.
Number of hematological and biochemical laboratory assessment Abnormalities reported as AEs during the quarantine period.
Measured: Day -2 to Day12
Use of Concomitant Medication
Concomitant medications (prescription and over the counter drugs and supplements that a study participant had taken alongside the study vaccination) were recorded for the period following vaccination (up to viral challenge) and from viral challenge until Day 28..
Measured: From Vaccination (Day -28) until Viral Challenge (Day 0), and From Viral Challenge (Day 0) until Day 28
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Mar 2021
- Study start10 Nov 2020
- Primary completion8 Apr 2021
- Study completion16 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Respiratory Syncytial Virus InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 70 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hvivo
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Pfizer
- Responsible party
- Sponsor
- Investigators
- Alex Mann, Study director, HvivoGolam Kabir, MD, Principal investigator, Hvivo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04785612
- Sponsor's protocol ID
- HVO-CS-005
- Status last verified
- Feb 2024
- First submitted
- 12 Feb 2021
- Last updated
- 7 Aug 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154.
PubMed 35731653
Study at a glance
From the registry record, last updated by the sponsor on 7 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in Healthy Adults
- ClinicalTrials.gov ID
- NCT04785612
- Acronym / sponsor ID
- HVO-CS-005
- Conditions
- Respiratory Syncytial Virus Infections
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 70 participants (actual)
- Lead sponsor
- HvivoIndustry (pharma, biotech, devices)
- Collaborators
- Pfizer
- Study start
- 10 Nov 2020 (actual)
- Primary completion
- 8 Apr 2021 (actual)
- Study completion
- 16 Aug 2021 (actual)
- First posted
- 8 Mar 2021 (actual)
- Results
- Posted 7 Aug 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this randomised, placebo-controlled, double-blind Phase 2a study, healthy male and female participants 18-50 years of age will be given an investigational RSV vaccine (RSVpreF) and challenged with RSV one month later. The purpose of this research study is to assess the safety, immunogenicity and efficacy of RSVpreF using a human viral challenge model.
Detailed description
Respiratory Syncytial Virus (RSV) is a common virus that affects all human age groups and can cause a range of respiratory disease such as bronchitis and lower respiratory infections. These serious illnesses affect infants and adults who are older especially if they are over 65, have chronic heart or lung disease or have a weakened immune system. Vaccination against RSV has the potential to be a highly beneficial and effective approach to reduce RSV disease in older adults and pediatric populations, however there is no current vaccine approved for the prevention of RSV infections.
RSVpreF is being developed to prevent RSV-associated moderate to severe lower respiratory tract disease in adults 60 years of age and in infants by active immunization of pregnant women.
This study is an exploratory proof-of-concept to assess the safety, immunogenicity and efficacy of RSVpreF using a human challenge model. The RSV challenge model is developed to help understanding the RSV disease and assess new vaccines by testing them in participants deliberately infected with the virus.
In this study, approximately 62 (up to 72) participants will be vaccinated with the investigational RSVpreF to account for withdrawals between vaccination and challenge. Participants will be randomised 1:1 to receive RSVpreF or placebo.
The study will consist of a vaccination phase, quarantine phase and a follow-up phase.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| RSVPreF | Experimental | Biological: RSVPreFA single intramuscular injection at a dose of 120 mcg reconstituted with sterile water for an 0.5 mL injection volume |
| Placebo | Placebo comparator | Other: PlaceboA single intramuscular injection of Placebo to match active vaccine |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (16 listed)
- An informed consent document signed and dated by the participant and the Investigator.
- Aged between 18 and 50 years.
- In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety.
- A documented medical history prior to enrolment.
- The following criteria are applicable to female participants participating in the study.
Key exclusion criteria (25 listed)
- History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit.
- a) Any history or evidence of any other clinically significant or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety).
- Participants who have smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years].
- A total body weight ≤ 50 kg and Body Mass Index (BMI) ≤18 kg/m2 and ≥30kg/m2.
- Females who:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RSVPreFA single dose of 120 mcg RSVpreF for intramuscular injection | Biological | RSVPreF |
| PlaceboA single Placebo dose for intramuscular injection to match experimental vaccine | Other | Placebo |
Primary outcome
Area Under the Viral Load-time Curve (VL-AUC) of RSV
Time frame: Day 2 to Day 12
The VL-AUC of RSV determined by qRT-PCR from nasal wash samples collected twice daily starting two days post-viral challenge (Day +2) up to discharge from quarantine.
Number of Participants With RT-PCR Confirmed (Detected) Incidence of Symptomatic Infection
Time frame: Day 2 to Day 12
RT-PCR-confirmed symptomatic RSV infection defined as: - Two detectable qRT-PCR reported on 2 or more consecutive days (any two detectable (≥LLOD) qRT-PCR measurements reported over 4 consecutive scheduled timepoints). and - Either one or more positive clinical symptoms from different categories in the symptom scoring system or one Grade 2 symptom from any category
Sum Total Symptoms Diary Card Score (TSS)
Time frame: Day 1 to Day 12
The sum total symptoms score is the sum of all scores from the first assessment on Day 1 to the first assessment on Day 12 (34 assessments). Symptom scores were collected three times daily starting one day post-viral challenge (Day +1) up to discharge from quarantine using a participant self-reportable 13-symptoms card. Clinical symptoms include runny nose, stuffy nose, sneezing, sore throat, earache, malaise/tiredness, headache, muscle or joint ache, chilliness/feverishness, cough, chest tightness, shortness of breath, and wheeze. Participants scored symptoms from 0 (no symptoms) - 3 (severe). Shortness of breath and wheeze had an additional scoring option of grade 4. For each assessment, an individual total symptom score was derived as the total of the scores given to the 13 symptoms on that symptom score card. Individual total symptom scores ranged from 0 (if all symptoms graded 0) to 41 (if all symptoms graded 3 and shortness of breath and wheeze graded 4).
24 secondary outcomes
Number of Participants With RT-PCR Confirmed (Quantifiable) Incidence of Symptomatic Infection
Time frame: Day 2 to Day 12
Number of Participants With Culture Lab-confirmed Reduction of Symptomatic RSV Infection
Time frame: Day 2 to Day 12
Peak Viral Load of RSV by qRT-PCR
Time frame: Day 2 to Day 12
Peak Viral Load of RSV by Viral Culture
Time frame: Day 2 to Day 12
Duration of Quantifiable qRT-PCR Measurements
Time frame: Day 2 to Day 12
Duration of Quantitative Viral Culture Measurements
Time frame: Day 2 to Day 12
VL-AUC Determined by Quantitative Viral Culture
Time frame: Day 2 to Day 12
Area Under the Curve Over Time of Total Clinical Symptoms (TSS-AUC)
Time frame: Day 1 to Day 12
Peak Symptoms Diary Card Score
Time frame: Day 1 to Day 12
Peak Daily Symptom Score
Time frame: Day 1 to Day 12
Percentage Number of Participants With Grade 2 or Higher Symptoms
Time frame: Day 1 to Day 12
Number of Participants With an Occurrence of at Least Two Positive Quantifiable qRT-PCR Measurements on 2 or More Consecutive Days
Time frame: Day 2 to Day 12
Number of Participants With an Occurrence of at Least Two Positive Detectable qRT-PCR Measurements on 2 or More Consecutive Days
Time frame: Day 2 to Day 12
Number of Participants With an Occurrence of at Least One Positive Quantitative Cell Culture Measurements
Time frame: Day 2 to Day 12
Total Mucus Weight
Time frame: Day 1 to Day 12
Total Tissue Number
Time frame: Day 1 to Day 12
Number of Solicited Local Reactions Within 7 Days After Vaccination
Time frame: 7 days post vaccination
Number of Systemic Events Within 7 Days After Vaccination
Time frame: 7 days post vaccination
Number of Participants With an Occurrence of Unsolicited Adverse Events (AEs) Post Vaccination
Time frame: 30 days
Occurrence of Medically Attended AEs
Time frame: Through study completion, an average of 6 months
Occurrence of SAEs
Time frame: Through study completion, an average of 6 months
Number of Participants With an Occurrence of Unsolicited AEs Related to Viral Challenge
Time frame: Day 0 to Day 28
Occurrence of Haematological and Biochemical Laboratory Abnormalities During the Quarantine Period.
Time frame: Day -2 to Day12
Use of Concomitant Medication
Time frame: From Vaccination (Day -28) until Viral Challenge (Day 0), and From Viral Challenge (Day 0) until Day 28
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Aug 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 35731653Schmoele-Thoma B, Zareba AM, Jiang Q, Maddur MS, Danaf R, Mann A, Eze K, Fok-Seang J, Kabir G, Catchpole A, Scott DA, Gurtman AC, Jansen KU, Gruber WC, Dormitzer PR, Swanson KA. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056/NEJMoa2116154.
Related trials for Respiratory Syncytial Virus Infections
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Active, not recruitingPhase 3
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
Respiratory Syncytial Virus Infections
Active, not recruitingPhase 1
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
Respiratory Syncytial Virus (RSV), Infectious Disease
RecruitingPhase 2
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
Respiratory Syncytial Virus (RSV)
RecruitingObservational study
TARSILA Real-World Evidence Study
Respiratory Syncytial Virus (RSV), Maternal Immunization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alex Mann study director
Hvivo
Golam Kabir, MD principal investigator
Hvivo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing RSVPreF in people with Respiratory Syncytial Virus Infections, run by Hvivo at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 7 Aug 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Viral Load-time Curve (VL-AUC) of RSV (time frame: Day 2 to Day 12). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04785612, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Aug 2024.